Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

Chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) represents a major public health issue; it develops in about 30%–40% of patients with diabetes mellitus and is the most common cause of CKD worldwide. Patients with CKD and T2D are at high risk of both developing kidney failure a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarafidis, Pantelis, Iatridi, Fotini, Ferro, Charles, Alexandrou, Maria-Eleni, Fernandez-Fernandez, Beatriz, Kanbay, Mehmet, Mallamaci, Francesca, Nistor, Ionut, Rossignol, Patrick, Wanner, Christoph, Cozzolino, Mario, Ortiz, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
CKJ Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616462/
https://www.ncbi.nlm.nih.gov/pubmed/37915899
http://dx.doi.org/10.1093/ckj/sfad139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616462/
https://www.ncbi.nlm.nih.gov/pubmed/37915899
http://dx.doi.org/10.1093/ckj/sfad139

Ejemplares similares